news

Phase 3 study of Opdivo in head and neck cancer meets primary endpoint

0
SHARES

Posted: 29 January 2016 | | No comments yet

The study demonstrated superior overall survival (OS) in patients receiving Opdivo compared to the control arm…

A Phase 3 study evaluating Bristol-Myers Squibb’s Opdivo (nivolumab) versus investigator’s choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) has been stopped early because the study met its primary endpoint.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

opdivo

The study demonstrated superior overall survival (OS) in patients receiving Opdivo compared to the control arm.

Commenting on the announcement, Michael Giordano, M.D., senior vice president, head of Oncology Development, Bristol-Myers Squibb, said: “With the results of CheckMate -141, Opdivo moves closer to providing a potential treatment option for patients with head and neck cancer, a cancer with a high unmet need and limited treatment options. We look forward to continuing to advance the Opdivo clinical development program in hard-to-treat cancers, such as head and neck cancer.”

CheckMate -141 is a Phase 3, open-label, randomised study of Opdivo versus investigator’s choice of therapy in previously treated patients with SCCHN who have tumour progression on or within 6 months of platinum therapy in the primary, recurrent, or metastatic setting. The trial randomised 361 patients 2:1 to receive either Opdivo 3 mg/kg intravenously every two weeks or investigator’s choice (cetuximab/methotrexate/docetaxel) until documented disease progression or unacceptable toxicity. The primary endpoint was OS. Secondary endpoints include objective response rate and progression free survival.

Opdivo is a PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T-cells, and blocks the binding of PD-L1 and PD-L2, preventing the PD-1 pathway’s suppressive signalling on the immune system, including the interference with an anti-tumour immune response.

Related topics

Related organisations

Share via
Share via